High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 6504-6504 ◽  
Author(s):  
A. Nademanee ◽  
S. J. Forman ◽  
A. Molina ◽  
N. Kogut ◽  
H. C. Fung ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Hematopoietic Cell ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Cell Transplant ◽  
Ibritumomab Tiuxetan ◽  
Hematopoietic Cell Transplant ◽  
Poor Risk ◽  
Yttrium 90

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

2007 ◽  
Vol 48 (9) ◽  
pp. 1736-1744 ◽  
Author(s):  
Jatin Shah ◽  
Wenquan Wang ◽  
V. Douglas Harrough ◽  
Wayne Saville ◽  
Ruby Meredith ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90
Sign in / Sign up

Export Citation Format

Share Document